Kala Bio KALA
NASDAQ KALA
$0.42 -0.01 (-2.37%)
As of: Oct 1, 2026 · 3:59 PM EDT

Kala Bio (KALA) Current Deferred Revenue (2022 - 2025)

Updated

Kala Bio's Current Deferred Revenue came in at $546,000 for Q1 2025, down 14.3% from the prior quarter.

Analysis

Kala Bio (KALA) Current Deferred Revenue (2022 - 2025) Analysis & Trends

At the end of FY2024, Kala Bio's Current Deferred Revenue was $637,000, down 40.7% from FY2023.

  • Going back by year, Current Deferred Revenue was $1.08 million in FY2023 (-74.3%) and $4.19 million in FY2022.
  • The five-year range for quarterly Current Deferred Revenue is $314,000 (Q3 2024) to $4.19 million (Q2 2023).
  • Business Quant data shows KALA's Current Deferred Revenue at $637,000 (Q4 2024), $314,000 (Q3 2024) and $2.26 million (Q2 2024) in the three quarters before Q1 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn
10 Kala Bio 6.57 Mn 6.57 Mn -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2025 546,000.00
Dec 31, 2024 637,000.00
Sep 30, 2024 314,000.00
Jun 30, 2024 2.26 Mn
Dec 31, 2023 1.08 Mn
Sep 30, 2023 2.93 Mn
Jun 30, 2023 4.19 Mn
Mar 31, 2023 4.19 Mn
Dec 31, 2022 4.19 Mn
Sep 30, 2022 3.41 Mn
API Access

Kala Bio Current Deferred Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=current-deferred-revenue&ticker=KALA&period=max&api_key=YOUR_API_KEY